2018, Number 6
PDF size: 644.27 Kb.
Text ExtractionThe ability to generate human papillomavirus (HPV) virus like particles (VLPs) by the synthesis and selfassembly in vitro of the major virus capsid protein L1 has transformed our prospects for preventing benign and malignant disease caused by HPV particularly the most prevalent HPV caused malignancy – cervical cancer in women. HPV L1 VLPs are structures geometrically and antigenically almost identical to the native virion but lack DNA and are therefore non-infectious. Three HPV L1 VLP prophylactic vaccines have been developed and are commercially available (figure 1); Cervarix, a bivalent HPV16/18 product (2vHPV) from GlaxoSmithKline Biologicals Rixensart Belgium, and Gardasil also known as Silgard, a quadrivalent HPV16/18/6/11 product (4vHPV) from MSD Merck, Whitehouse Station, New Jersey USA have been licensed since 2006/7 in the USA and Europe, Gardasil9 HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 a nonavalent product (9vHPV) licensed in 2014/15 in the USA and Europe.
Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017; 17(12):1293-302. https://doi.org/10.1016/S1473-3099(17)30468-1
Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-45. https://doi.org/10.1542/peds.2006-0461
Lazcano-Ponce E, Salmeron-Castro J, Garcia-Carranca A, Aranda-Flores C, Madrid-Marina V, Gomez-Altamirano CM, et al. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma en México. Salud Publica Mex. 2009;51(4):336-41. https://doi.org/10.1590/ S0036-36342009000400011
Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum Vaccin Immunother. 2015;11(3):732-8. https://doi.org/10.1080/21645515.2015.1011570
Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32(6):725-32. https://doi.org/10.1016/j.vaccine.2013.11.059
Hernandez-Avila M, Torres-Ibarra L, Stanley M, Salmeron J, Cruz-Valdez A, Munoz N, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30-8. https://doi.org/10.1080/21645515.2015.1058458
Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04- adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374-86. https://doi.org/10.4161/hv.7.12.18322
Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77. https://doi.org/10.1016/ S1470-2045(15)00414-3
Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent Human Papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: A prospective cohort study. Clin Infect Dis. 2017;64(7):852-9.